Caspofungin for Pneumocystis Pneumonia in PLWHIV.
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorInstituto Nacional de Enfermedades Respiratorias
About this trial
Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV/AIDS, often severe and potentially fatal. While trimethoprim/sulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.
Eligibility criteria
Qualifiers
Diagnosis of probable or proven PCP, according to its diagnostic classification (refer to classification at the end of this section).
Have clinical laboratory and virological diagnostic laboratory studies at the time of admission.
Disqualifiers
With a treatment switch to caspofungin after day 7 of treatment initiation (applies only to group B).
Patients who have developed an additional opportunistic lung infection during their hospitalization, other than cytomegalovirus pneumonitis or SARS-CoV-2 pneumonia.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
60 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov